Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer

被引:20
|
作者
Jeremic, B
Shibamoto, Y
机构
[1] KYOTO UNIV, CHEST DIS RES INST, DEPT ONCOL, KYOTO 60601, JAPAN
[2] UNIV HOSP, DEPT ONCOL, KRAGUJEVAC, YUGOSLAVIA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1996年 / 34卷 / 02期
关键词
radiotherapy; hyperfractionation; interfraction interval; nonsmall cell lung cancer;
D O I
10.1016/0360-3016(95)02158-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the influence of interfraction interval in hyperfractionated radiotherapy (HFX RT) with or without concurrent chemotherapy for Stage III nonsmall cell lung cancer. Methods and Materials: One hundred sixty-nine patients treated in a randomized study were retrospectively analyzed. Group I patients were treated by HFX RT with 1.2 Gy twice daily with a total dose of 64.8 Gy in 27 treatment days, while Groups II and III patients were treated by the same HFX RT and concurrent chemotherapy with carboplatin and etoposide (every week in Group II and every other week in Group III). Interfraction intervals of either 4.5-5 h or 5.5-6 h were used for each patient. Results: Patients treated with shorter interfraction intervals (4.5-5 h) had a better prognosis than those treated with longer intervals (5.5-6 h)(median survival: 22 vs. 7 months; 5-year survival rate: 27% vs. 0%, p = 0.00000). This phenomenon was observed in all treatment groups. Patients greater than or equal to 60 years of age, with Stage IIIA disease, or with previous weight loss less than or equal to 5% were treated more often with the shorter intervals than those < 60 years, with Stage IIIB disease, or with weight loss > 5%, respectively, but in all of these subgroups of patients, the shorter intervals were associated with a better prognosis. Multivariate analysis showed that the interfraction interval was an independent prognostic factor, together with sex, age, performance status, and stage, The shorter intervals were associated with an increased incidence of acute high grade toxicity, but not with an increase in late toxicity. Conclusion: Patients treated with shorter interfraction intervals (4.5-5 h) appeared to have a better survival than those treated with longer intervals (5.5-6 h). Prospective randomized studies are warranted to further investigate the influence of interfraction interval in HFX RT.
引用
收藏
页码:303 / 308
页数:6
相关论文
共 50 条
  • [41] PREOPERATIVE CONCOMITANT CISPLATIN VP16 AND RADIOTHERAPY IN STAGE-III NONSMALL CELL LUNG-CANCER
    PALAZZI, M
    CATALDO, I
    GRAMAGLIA, A
    DETOMA, D
    MILANI, F
    RAVASI, G
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 (03): : 621 - 625
  • [42] EFFECT OF RADIOLOGIC STAGE-III SUBSTAGE ON NONSURGICAL THERAPY OF NONSMALL CELL LUNG-CANCER
    KREISMAN, H
    LISBONA, A
    OLSON, L
    PROPERT, KJ
    MODEAS, C
    DILLMAN, RO
    SEAGREN, SL
    GREEN, MR
    CANCER, 1993, 72 (05) : 1588 - 1596
  • [43] Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancer
    De Pauw, Rebecca
    van Meerbeeck, Jan P.
    CURRENT OPINION IN ONCOLOGY, 2007, 19 (02) : 92 - 97
  • [44] RADIATION-THERAPY AND CONCURRENT CISPLATIN IN STAGE-III INOPERABLE NONSMALL CELL LUNG-CANCER - A PHASE-III STUDY
    REBOUL, F
    VINCENT, P
    CHAUVET, B
    BREWER, Y
    SERIN, D
    FELIXFAURE, C
    TAULELLE, M
    BULLETIN DU CANCER, 1995, 82 (03) : 196 - 201
  • [45] CONCURRENT HYPERFRACTIONATED IRRADIATION AND CHEMOTHERAPY FOR UNRESECTABLE NONSMALL-CELL LUNG-CANCER - RESULTS OF RADIATION-THERAPY ONCOLOGY GROUP-90-15
    BYHARDT, RW
    SCOTT, CB
    ETTINGER, DS
    CURRAN, WJ
    DOGGETT, RLS
    COUGHLIN, C
    SCARANTINO, C
    ROTMAN, M
    EMAMI, B
    CANCER, 1995, 75 (09) : 2337 - 2344
  • [46] HYPERFRACTIONATED SPLIT-COURSE THORACIC RADIATION-THERAPY PLUS CHEMOTHERAPY IN LOCALLY ADVANCED NONSMALL CELL LUNG-CANCER
    IAFFAIOLI, RV
    TORTORIELLO, A
    FACCHINI, G
    CAPONIGRO, F
    FRASCI, G
    PANELLI, G
    RAVO, V
    MUTO, P
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1994, 4 (03) : 577 - 582
  • [47] Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for stage III and IVA head-and-neck cancer in the community
    Maguire, PD
    Meyerson, MB
    Neal, CR
    Hamann, MS
    Bost, AL
    Anagnost, JW
    Ungaro, PC
    Pollock, HD
    McMurray, JE
    Wilson, EP
    Kotwall, CA
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (03): : 698 - 704
  • [48] Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma
    Raoul, JL
    Le Prisé, E
    Meunier, B
    Heresbach, D
    Campion, JP
    Launois, B
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 42 (01): : 29 - 34
  • [49] Chemotherapy in elderly patients with nonsmall cell lung cancer
    Veluswamy, Rajwanth R.
    Levy, Benjamin
    Wisnivesky, Juan P.
    CURRENT OPINION IN PULMONARY MEDICINE, 2016, 22 (04) : 336 - 343
  • [50] Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients
    Jeremic, Branislav
    Milicic, Biljana
    Milisavljevic, Slobodan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (08) : 613 - 618